In some Merck Keytruda related news, this from Immutep this morning:
As announced concurrently with this equity raising, Immutep has entered a Clinical Trial Collaboration and Supply Agreement with MSD (Merck & Co., Rahway, NJ, USA) (MSD Agreement), through a subsidiary, for the pivotal Phase III TACTI-004 trial in 1L NSCLC. Immutep will retain commercial freedom for the global rights to efti (ex-China).
Under the terms of the MSD Agreement, MSD will provide the Company with supply of KEYTRUDA® at MSD's cost. Immutep estimates the typical value of Immune Checkpoint Inhibitor (ICI) drug supply for a Phase III trial of this size to be approximately US$100m (A$150m). In addition to drug supply, MSD will also share clinical, scientific and regulatory resources with the Company.
Media Thread, page-13944
-
- There are more pages in this discussion • 1,608 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $379.2M | |||
| Open | High | Low | Value | Volume |
| 5.2¢ | 5.2¢ | 5.0¢ | $1.098M | 21.50M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 97 | 7481668 | 5.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.1¢ | 1703097 | 4 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |